Human Biomarker Exposure from Cigarettes Versus Novel Heat-Not-Burn Devices: A Systematic Review and Meta-Analysis

Nicotine and Tobacco Research

Volumn 22, Issue 7, 2020, Pages 1077-1085

  Drovandi, Aaron ^a   Salem, Saad ^b   Barker, Daniel ^c   Booth, Debbie ^d   Kairuz, Therese ^b  

^a JAMES COOK UNIVERSITY   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; NICOTINE;

EXPOSURE; HEATING; HUMAN; META ANALYSIS; POLICY; PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY CONTROL; REVIEW; SAFETY; SMOKING CESSATION; SMOKING HABIT; SYSTEMATIC REVIEW; TOBACCO INDUSTRY; TREND STUDY; COMPARATIVE STUDY; ELECTRONIC CIGARETTE; HEAT; PREVENTION AND CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TOBACCO; TOBACCO USE;

BIOMARKERS; ELECTRONIC NICOTINE DELIVERY SYSTEMS; HOT TEMPERATURE; HUMANS; NICOTINE; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOBACCO PRODUCTS; TOBACCO USE;

EID: 85084811860     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntz200     Document Type: Review

References (52)

1. World Health Organization. WHO Report on the Global Tobacco Epidemic, 2017: Monitoring Tobacco Use and Prevention Policies. Geneva, Switzerland: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.
2. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ. 2004;328(7455):1519.
3. Lerman C, Caporaso NE, Audrain J, et al. Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol. 1999;18(1):14-20.
4. Strand BH, Mishra G, Kuh D, et al. Smoking history and physical performance in midlife: results from the British 1946 birth cohort. J Gerontol A Biol Sci Med Sci. 2010;66(1):142-149.
5. Mackay J, Eriksen M; WHO (World Health Organization). The Tobacco Atlas. Geneva, Switzerland: World Health Organization; 2002. http://www.who.int/tobacco/resources/publications/tobaccoátlas/en/. Accessed September 3, 2018.
6. World Health Organization. WHO Framework Convention on Tobacco Control. Geneva, Switzerland: World Health Organization; 2003. http://apps.who.int/iris/bitstream/10665/42811/1/9241591013.pdf?ua=1. Accessed September 8, 2018.
7. Pollay RW. Targeting youth and concerned smokers: evidence from Canadian tobacco industry documents. Tob Control. 2000;9(2):136-147.
8. Wakefield M, Morley C, Horan JK, et al. The cigarette pack as image: new evidence from tobacco industry documents. Tob Control. 2002;11(suppl 1):i73-80.
9. Perry CL. The tobacco industry and underage youth smoking: tobacco industry documents from the Minnesota litigation. Arch Pediatr Adolesc Med. 1999;153(9):935-941.
10. Hastings G, MacFadyen L. A day in the life of an advertising man: review of internal documents from the UK tobacco industry's principal advertising agencies. BMJ. 2000;321(7257):366-371.
11. Philip Morris International Heated Tobacco Products. https://www. pmi.com/science-and-innovation/heated-tobacco-products. Accessed September 3, 2018.
12. Breland AB, Kleykamp BA, Eissenberg T. Clinical laboratory evaluation of potential reduced exposure products for smokers. Nicotine Tob Res. 2006;8(6):727-738.
13. Haig M. Brand Failures: The Truth about the 100 Biggest Branding Mistakes of All Time. London, United Kingdom: Kogan Page Publishers; 2003.
14. Murguía SJ. Epic Fails: The Edsel, the Mullet, and Other Icons of Unpopular Culture. London, United Kingdom: Rowman & Littlefield; 2018.
15. Caputi TL. Industry watch: heat-not-burn tobacco products are about to reach their boiling point. Tob Control. 2017;26(5):609-610.
16. Institute of Medicine. Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction. Washington, DC: National Academy Press; 2001. http://www.nationalacademies.org/hmd/Reports/2001/Clearingthe-Smoke-The-Science-Base-for-Tobacco-Harm-Reduction.aspx. Accessed May 10, 2019.
17. McNeill A, Munafò MR. Reducing harm from tobacco use. J Psychopharmacol. 2013;27(1):13-18.
18. Simonavicius E, McNeill A, Shahab L, et al. Heat-not-burn tobacco products: a systematic literature review. Tob Control. 2019;28(5):582-594. doi:10.1136/tobaccocontrol-2018-054419.
19. Popova L, Lempert LK, Glantz SA. Light and mild redux: heated tobacco products' reduced exposure claims are likely to be misunderstood as reduced risk claims. Tob Control. 2018;27(Suppl1):s87-s95. doi:10.1136/tobaccocontrol-2018-054324.
20. Caputi TL, Leas E, Dredze M, Cohen JE, Ayers JW. They're heating up: Internet search query trends reveal significant public interest in heat-notburn tobacco products. PLoS One. 2017;12(10):e0185735.
21. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med. 2009;151(4):264-269, W64.
22. Tufanaru C, Munn Z, Aromataris E, et al. Chapter 3: Systematic reviews of effectiveness. In: Aromataris E, Munn Z, eds. Joanna Briggs Institute Reviewer's Manual. The Joanna Briggs Institute; 2017. https://reviewersmanual.joannabriggs.org/. Accessed August 12, 2019.
23. Carlson KD, Schmidt FL. Impact of experimental design on effect size: findings from the research literature on training. J Appl Psychol. 1999;84(6):851.
24. Hedges LV. Distribution theory for Glass's estimator of effect size and related estimators. J Educ Stat. 1981;6(2):107-128.
25. Morris SB. Estimating effect sizes from pretest-posttest-control group designs. Organ Res Methods. 2008;11(2):364-386.
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
27. Sakaguchi C, Kakehi A, Minami N, Kikuchi A, Futamura Y. Exposure evaluation of adult male Japanese smokers switched to a heated cigarette in a controlled clinical setting. Regul Toxicol Pharmacol. 2014;69(3):338-347.
28. Haziza C, de La Bourdonnaye G, Merlet S, et al. Assessment of the reduction in levels of exposure to harmful and potentially harmful constituents in Japanese subjects using a novel tobacco heating system compared with conventional cigarettes and smoking abstinence: a randomized controlled study in confinement. Regul Toxicol Pharmacol. 2016;81:489-499.
29. Haziza C, de La Bourdonnaye G, Skiada D, et al. Evaluation of the Tobacco Heating System 2.2. Part 8: 5-day randomized reduced exposure clinical study in Poland. Regul Toxicol Pharmacol. 2016;81(suppl 2):S139-S150.
30. Lüdicke F, Haziza C, Weitkunat R, Magnette J. Evaluation of biomarkers of exposure in smokers switching to a carbon-heated tobacco product: a controlled, randomized, open-label 5-day exposure study. Nicotine Tob Res. 2016;18(7):1606-1613.
31. Lüdicke F, Baker G, Magnette J, Picavet P, Weitkunat R. Reduced exposure to harmful and potentially harmful smoke constituents with the tobacco heating system 2.1. Nicotine Tob Res. 2017;19(2):168-175.
32. Gale N, McEwan M, Eldridge AC, et al. Changes in biomarkers of exposure on switching from a conventional cigarette to tobacco heating products: a randomized, controlled study in healthy Japanese subjects. Nicotine Tob Res. 2019;21(9):1220-1227. doi:10.1093/ntr/nty104.
33. Lüdicke F, Picavet P, Baker G, et al. Effects of switching to the tobacco heating system 2.2 menthol, smoking abstinence, or continued cigarette smoking on biomarkers of exposure: a randomized, controlled, openlabel, multicenter study in sequential confinement and ambulatory settings (Part 1). Nicotine Tob Res. 2018;20(2):161-172.
34. Yuki D, Takeshige Y, Nakaya K, Futamura Y. Assessment of the exposure to harmful and potentially harmful constituents in healthy Japanese smokers using a novel tobacco vapor product compared with conventional cigarettes and smoking abstinence. Regul Toxicol Pharmacol. 2018;96:127-134.
35. Haziza C, De La Bourdonnaye G, Donelli A, et al. Reduction in exposure to selected harmful and potentially harmful constituents approaching those observed upon smoking abstinence in smokers switching to the menthol tobacco heating system 2.2 for 3 months (Part 1). Nicotine Tob Res. 2020;22(4):539-548.
36. Lüdicke F, Ansari SM, Lama N, et al. Effects of switching to a heat-notburn tobacco product on biologically-relevant biomarkers to assess a candidate modified risk tobacco product: a randomized trial. Cancer Epidemiol Biomarkers Prev. 2019;28(11):1934-1943. doi:10.1158/1055-9965.EPI-18-0915.
37. Haziza C, de La Bourdonnaye G, Skiada D, et al. Biomarker of exposure level data set in smokers switching from conventional cigarettes to Tobacco Heating System 2.2, continuing smoking or abstaining from smoking for 5 days. Data Brief. 2017;10:283-293.
38. Murphy J, Gaca M, Lowe F, et al. Assessing modified risk tobacco and nicotine products: description of the scientific framework and assessment of a closed modular electronic cigarette. Regul Toxicol Pharmacol. 2017;90:342-357.
39. Wills TA, Knight R, Williams RJ, Pagano I, Sargent JD. Risk factors for exclusive e-cigarette use and dual e-cigarette use and tobacco use in adolescents. Pediatrics. 2015;135(1):e43-e51.
40. Measham F, O'Brien K, Turnbull G. "Skittles & Red Bull is my favourite flavour": e-cigarettes, smoking, vaping and the changing landscape of nicotine consumption amongst British teenagers-implications for the normalisation debate. Drugs. 2016;23(3):224-237.
41. Turner JA, Sillett RW, McNicol MW. Effect of cigar smoking on carboxyhaemoglobin and plasma nicotine concentrations in primary pipe and cigar smokers and ex-cigarette smokers. Br Med J. 1977;2(6099):1387-1389.
42. Fawcett TA, Moon RE, Fracica PJ, Mebane GY, Theil DR, Piantadosi CA. Warehouse workers' headache. Carbon monoxide poisoning from propane-fueled forklifts. J Occup Med. 1992;34(1):12-15.
43. Allred EN, Bleecker ER, Chaitman BR, et al. Short-term effects of carbon monoxide exposure on the exercise performance of subjects with coronary artery disease. N Engl J Med. 1989;321(21):1426-1432.
44. Centers for Disease Control and Prevention. NIOSH Pocket Guide to Chemical Hazards: Beta-naphthylamine. 2018. https://www.cdc.gov/niosh/npg/npgd0442.html. Accessed May 25, 2019.
45. US Department of Health and Human Services National Toxicology Program. 14th Report on Carcinogens, 2016. https://ntp.niehs.nih.gov/ntp/roc/content/profiles/aminobiphenyl.pdf. Accessed August 8, 2019.
46. US Department of Human and Health Services National Toxicology Program. Final Report on Carcinogens Background Document for Environmental Tobacco Smoke, 1998. https://ntp.niehs.nih.gov/ntp/newhomeroc/other-background/environmentalts-noapps-508.pdf. Accessed August 8, 2019.
47. Caponnetto P, Maglia M, Prosperini G, Busà B, Polosa R. Carbon monoxide levels after inhalation from new generation heated tobacco products. Respir Res. 2018;19(1):164.
48. Adriaens K, Gucht DV, Baeyens F. IQOSTM vs. e-cigarette vs. tobacco cigarette: a direct comparison of short-term effects after overnightabstinence. Int J Environ Res Public Health. 2018;15(12):2902.
49. Hendlin YH, Vora M, Elias J, Ling PM. Financial conflicts of interest and stance on tobacco harm reduction: a systematic review. Am J Public Health. 2019;109(7):e1-e8.
50. Lasseter T, Bansal P, Wilson T, et al. Special Report: Scientists Describe Problems in Philip Morris E-Cigarette Experiments. 2017. https://www. reuters.com/article/us-tobacco-iqos-science-specialreport/special-reportscientists-describe-problems-in-philip-morris-e-cigarette-experimentsidUSKBN1EE1GG? utm-source=applenews. Accessed January 30, 2019.
51. Elias J, Dutra LM, St Helen G, Ling PM. Revolution or redux? Assessing IQOS through a precursor product. Tob Control. 2018;27(suppl 1):s102-s110.
52. Helen GS, Jacob III P, Nardone N, et al. IQOS: Examination of Philip Morris International's claim of reduced exposure. Tob Control. 2018;27(suppl 1):s30-36.